Figure 4.
Figure 4. The chimeric and deimmunized forms of Leu16-IL-2 have similar antitumor activity. SCID mice were injected with Daudi lymphoma cells and treated with the indicated antibody or immunocytokine beginning 7 days later. Treatments included PBS only (×; on days 7-11); rituximab (♦; 25 mg/kg on days 7, 9, and 11); medium-dose DI-Leu16-IL-2 (▪; 1 mg/kg on days 7-11); low-dose DI-Leu16-IL-2 (□; 0.25 mg/kg on days 7-11); medium-dose chLeu16-IL-2 (▴; 1 mg/kg on days 7-11); and low-dose chLeu16-IL-2 (▵; 0.25 mg/kg on days 7-11). The higher dose groups of both the chimeric and DI forms of Leu16-IL-2 were significantly different from all other groups (P < .005 or less). The lower doses were not significantly different from each other but the chLeu16-IL-2 group was significantly different from the rituximab control (P < .0025). All treatment groups were significantly different from the PBS control (P < .025 or less).

The chimeric and deimmunized forms of Leu16-IL-2 have similar antitumor activity. SCID mice were injected with Daudi lymphoma cells and treated with the indicated antibody or immunocytokine beginning 7 days later. Treatments included PBS only (×; on days 7-11); rituximab (♦; 25 mg/kg on days 7, 9, and 11); medium-dose DI-Leu16-IL-2 (▪; 1 mg/kg on days 7-11); low-dose DI-Leu16-IL-2 (□; 0.25 mg/kg on days 7-11); medium-dose chLeu16-IL-2 (▴; 1 mg/kg on days 7-11); and low-dose chLeu16-IL-2 (▵; 0.25 mg/kg on days 7-11). The higher dose groups of both the chimeric and DI forms of Leu16-IL-2 were significantly different from all other groups (P < .005 or less). The lower doses were not significantly different from each other but the chLeu16-IL-2 group was significantly different from the rituximab control (P < .0025). All treatment groups were significantly different from the PBS control (P < .025 or less).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal